Utility of C-terminal Telopeptide in Evaluating Levothyroxine Replacement Therapy-Induced Bone Loss | Zendy

Alap Christy | Zendy; Vivian D’Souza | Zendy; Ruby P. Babu | Zendy; Sohil Takodara | Zendy; Poornima Manjrekar | Zendy; Anupama Hegde | Zendy; M S Rukmini | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Utility of C-terminal Telopeptide in Evaluating Levothyroxine Replacement Therapy-Induced Bone Loss

Author(s) -

Alap Christy,

Vivian D’Souza,

Ruby P. Babu,

Sohil Takodara,

Poornima Manjrekar,

Anupama Hegde,

M S Rukmini

Publication year - 2014

Publication title -

biomarker insights

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.075

H-Index - 31

ISSN - 1177-2719

DOI - 10.4137/bmi.s13965

Subject(s) - medicine , levothyroxine , n terminal telopeptide , bone remodeling , osteoporosis , euthyroid , bone mineral , bone resorption , type i collagen , endocrinology , urology , osteocalcin , hormone , biochemistry , chemistry , alkaline phosphatase , enzyme

Levothyroxine (LT4) therapy has shown to have effects on bone metabolism though its deleterious effect on bone remodeling is debatable. This study was aimed at assessing the diagnostic utility of the bone remodeling marker C-terminal telopeptide (CTx) in detecting early bone loss.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research